PERSICA PHARMACEUTICALS LIMITED published new analyses highlighting the strong exposure-response relationship between estimated intradiscal antibiotic exposure and clinical outcomes for vertebrogenic Lumbar Back Pain (vLBP).
Published
Signal category
Research & Knowledge
Quote
“Great to share news of this new analyses which supports a deeper understanding of the published literature and highlights the strong exposure-response relationship between estimated intradiscal antibiotic exposure and clinical outcomes for vertebrogenic Lumbar Back Pain (vLBP).”
— Dave Watson|PERSICA PHARMACEUTICALS LIMITED team
Company
PERSICA PHARMACEUTICALS LIMITED
Developing a transformative, non-opioid treatment for patients suffering from chronic Low Back Pain with Modic changes
- Industry
- Biotechnology Research
- Company size
- 11 employees
Persica Pharmaceuticals is a clinical-stage company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic changes. PP353 is a non-opioid, one-off treatment which addresses an underlying cause of cLBP, rather than just the symptoms. Our Phase 1b study, the #Modic trial, showed statistically significant and clinically meaningful reductions in pain and disability. We are now in discussions with regulators about advancing to registrational trials.